Hangzhou Tigermed Consulting Co., Ltd. Class H (3347) AI Stock Analysis

• Market Cap: HK$52.82B
• Dividend Yield: 0.8%
• Average Volume (3M): 2.64M
• Price to Earnings (P/E): 65.2
• Beta (1Y): 1.79
• Revenue Growth: -3.81%
• EPS Growth: -34.76%
• Country: HK
• Employees: 10,185
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.81
• Shares Outstanding: 123,124,800
• 10 Day Avg. Volume: 1,735,173
• 30 Day Avg. Volume: 2,642,557
• PEG Ratio: -0.77
• Price to Book (P/B): 1.21
• Price to Sales (P/S): 3.79
• P/FCF Ratio: 33.79
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$52.88
• Price Target Upside: 3.78% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: HK$54.00 ▲(5.99% Upside)

The score is driven primarily by solid margins and a strong, low-leverage balance sheet, offset by weakening TTM growth and operating cash flow. Technicals are supportive but overbought, and valuation is a meaningful headwind due to the high P/E and low yield.

Positive Factors

Strong Margins

Sustained strong gross and EBIT margins indicate efficient cost structures and pricing power in CRO services. This durable operational profitability supports reinvestment in trial capabilities, buffers margin volatility, and underpins long-term cash generation even if growth slows.

Low Financial Leverage

A low debt-to-equity ratio and high equity ratio provide long-term financial flexibility for capitalizing on new trials, partnerships, or regulatory demands. Low leverage reduces refinancing risk and preserves capacity to fund strategic investments during sector cycles.

Positive Free Cash Flow

Maintained positive free cash flow, even if reduced, demonstrates the business can convert earnings into cash. That durable cash generation supports R&D/service expansion, funds working capital needs for multi-period trials, and limits dependency on external financing.

Negative Factors

Declining Revenue and Net Income

TTM declines in revenue and net income signal weakening top-line momentum and reduced scale in core CRO services. Over months, this can erode competitive positioning, pressure utilization of trial staff, and limit pricing leverage unless new client wins or service diversification reverse the trend.

Weakened Operating Cash Flow

A significant drop in operating cash flow undermines the firm's ability to finance ongoing clinical operations and absorb longer trial timelines. Persistently lower cash from operations increases reliance on balance sheet liquidity and could constrain growth investments or bidding competitiveness.

Declining Return on Equity

Falling ROE suggests the company is generating lower returns on shareholder capital, potentially from slower growth or margin pressure. Over time, this can signal inefficiencies in capital allocation and may require strategic shifts to restore profitable growth and improve shareholder returns.

Hangzhou Tigermed Consulting Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

How the Company Makes Money

Hangzhou Tigermed Consulting Co., Ltd. generates revenue primarily through service fees associated with clinical trial management and consulting services. Its revenue model is built on a combination of project-based fees and retainer agreements with clients in the pharmaceutical and biotechnology sectors. Key revenue streams include clinical trial services, regulatory consulting, data management services, and post-marketing surveillance. Additionally, Tigermed has formed strategic partnerships with various pharmaceutical companies and research institutions, which enhance its service offerings and contribute to its earnings. The company may also benefit from government contracts and grants aimed at supporting clinical research initiatives.

Hangzhou Tigermed Consulting Co., Ltd. Class H Financial Statement Overview

Summary

Hangzhou Tigermed Consulting Co., Ltd. Class H demonstrates strong operational margins and a solid balance sheet, highlighting financial prudence. However, declining revenues and net income in the TTM, coupled with reduced operating cash flow, pose challenges for future growth and liquidity. Strengthening revenue generation and cash flow will be critical for sustaining financial health.

Income Statement

The company's gross profit margin and EBIT margin are strong, indicating efficient cost management and operational performance. However, revenue and net income have declined in the TTM, showing a negative growth trend. Despite this, the company maintains a healthy EBITDA margin, suggesting resilience in operational profitability.

Balance Sheet

The debt-to-equity ratio is low, indicating prudent financial leverage. The equity ratio is high, reflecting financial stability and strong asset backing. Return on equity has declined, suggesting a need for improved profitability to enhance shareholder returns.

Cash Flow

Operating cash flow has decreased significantly in the TTM, raising concerns about cash generation from core operations. The free cash flow to net income ratio is positive, but lower operating cash flow may impact future liquidity. The company has maintained positive free cash flow, albeit at a reduced level.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.73B	6.60B	7.38B	7.09B	5.21B	3.19B
Gross Profit	1.78B	2.24B	2.85B	2.81B	2.27B	1.51B
EBITDA	1.36B	1.13B	2.91B	2.93B	3.90B	1.27B
Net Income	1.08B	405.14M	2.02B	2.01B	2.87B	1.75B
Balance Sheet
Total Assets	31.46B	28.67B	29.68B	27.45B	23.74B	19.51B
Cash, Cash Equivalents and Short-Term Investments	1.86B	2.13B	7.46B	7.88B	8.57B	10.15B
Total Debt	1.91B	2.63B	2.83B	2.80B	1.19B	384.94M
Total Liabilities	4.46B	4.61B	5.23B	4.77B	3.14B	1.65B
Stockholders Equity	23.15B	20.67B	21.03B	19.58B	18.12B	16.12B
Cash Flow
Free Cash Flow	1.19B	740.45M	836.68M	908.90M	1.06B	842.18M
Operating Cash Flow	933.90M	1.10B	1.15B	1.36B	1.42B	998.68M
Investing Cash Flow	1.31B	-4.74B	-1.53B	―	―	―
Financing Cash Flow	-1.62B	-1.70B	-7.81M	809.25M	―	9.34B

Hangzhou Tigermed Consulting Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 50.95
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3347, the sentiment is Positive. The current price of 50.95 is above the 20-day moving average (MA) of 42.71, above the 50-day MA of 42.01, and above the 200-day MA of 40.93, indicating a bullish trend. The MACD of 2.28 indicates Negative momentum. The RSI at 77.12 is Negative, neither overbought nor oversold. The STOCH value of 93.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3347.

Hangzhou Tigermed Consulting Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2276	72 Outperform	HK$26.13B	45.22	24.57%	0.63%	13.58%	24.59%
2367	66 Neutral	HK$36.40B	14.47	29.64%	1.84%	36.70%	22.26%
6821	65 Neutral	HK$40.84B	27.16	6.00%	1.57%	12.35%	34.32%
3347	64 Neutral	HK$52.82B	65.18	2.72%	0.80%	-3.81%	-34.76%
3759	59 Neutral	HK$58.34B	25.02	10.94%	1.04%	14.50%	-19.24%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Hangzhou Tigermed Consulting Co., Ltd. Class H Corporate Events

Hangzhou Tigermed Releases 2025 Q3 Financial Report

Hangzhou Tigermed Consulting Co., Ltd. has released its third quarterly report for the financial year 2025. The report, prepared in accordance with Chinese accounting standards, remains unaudited and highlights the company’s ongoing operations. This announcement is crucial for shareholders and public investors, providing insights into the company’s financial health and strategic direction.

The most recent analyst rating on (HK:3347) stock is a Buy with a HK$62.10 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.

Hangzhou Tigermed to Review Q3 Financials on October 28, 2025

Hangzhou Tigermed Consulting Co., Ltd. has announced that its board of directors will convene on October 28, 2025, to discuss and approve the company’s third quarterly report for the period ending September 30, 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting stakeholders and the company’s positioning in the consulting industry.

The most recent analyst rating on (HK:3347) stock is a Buy with a HK$62.10 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.

Tigermed Announces Strategic Disposal to Enhance Operational Efficiency

Hangzhou Tigermed Consulting Co., Ltd. announced a share transfer agreement where its subsidiary, Jiaxing Xinge Medical Consulting Co., Ltd., will sell the entire issued share capital of Teddy Clinical Research Laboratory (Shanghai) Ltd. to Frontage Laboratories (Shanghai) Co., Ltd., a subsidiary of Frontage Holdings Corporation, for RMB270,000,000. This intra-group transaction is expected to optimize resource allocation, enhance operational efficiency, and promote synergies within the Group by consolidating the Target Group’s operations under the Frontage Group, thereby improving cost efficiency and operational focus.

The most recent analyst rating on (HK:3347) stock is a Hold with a HK$50.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.